Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $17.11, for a total transaction of $85,550.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Sangamo Therapeutics Inc (NASDAQ SGMO) traded down $0.10 on Thursday, reaching $17.30. 277,163 shares of the company traded hands, compared to its average volume of 1,441,714. The stock has a market cap of $1,460.00, a price-to-earnings ratio of -25.07 and a beta of 3.15. Sangamo Therapeutics Inc has a 12-month low of $3.35 and a 12-month high of $18.69. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. Sangamo Therapeutics’s revenue was up 333.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) EPS. research analysts anticipate that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current year.

Several brokerages have recently weighed in on SGMO. BidaskClub cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays began coverage on shares of Sangamo Therapeutics in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 price target on the stock. Wedbush reissued a “hold” rating and set a $6.00 price target on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Piper Jaffray Companies set a $25.00 price target on shares of Sangamo Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Finally, Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Wednesday, November 15th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $18.83.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Sangamo Therapeutics by 12.4% in the 2nd quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after buying an additional 384,031 shares during the period. State Street Corp increased its stake in Sangamo Therapeutics by 51.6% during the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after purchasing an additional 636,296 shares during the period. RA Capital Management LLC purchased a new stake in Sangamo Therapeutics during the second quarter worth about $11,000,000. Northern Trust Corp increased its stake in Sangamo Therapeutics by 4.9% during the second quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock worth $8,341,000 after purchasing an additional 44,656 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in Sangamo Therapeutics by 93.8% during the third quarter. Point72 Asset Management L.P. now owns 693,300 shares of the biopharmaceutical company’s stock worth $10,400,000 after purchasing an additional 335,595 shares during the period. Hedge funds and other institutional investors own 64.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of Stock” was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/11/insider-selling-sangamo-therapeutics-inc-sgmo-vp-sells-5000-shares-of-stock.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply